531 related articles for article (PubMed ID: 34022793)
1. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Li J; Wang P; Tracey KJ; Wang H
Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction.
Qiang X; Zhu S; Li J; Chen W; Yang H; Wang P; Tracey KJ; Wang H
J Leukoc Biol; 2022 Jan; 111(1):261-267. PubMed ID: 33759207
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
6. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
Mondal T; Shivange G; Habieb A; Tushir-Singh J
Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
[TBL] [Abstract][Full Text] [Related]
7. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
Front Immunol; 2021; 12():719077. PubMed ID: 34394127
[TBL] [Abstract][Full Text] [Related]
8. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
9. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
10. The emerging plasticity of SARS-CoV-2.
McCormick KD; Jacobs JL; Mellors JW
Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
[No Abstract] [Full Text] [Related]
11. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
[TBL] [Abstract][Full Text] [Related]
12. Structure and function analysis of a potent human neutralizing antibody CA521
Song D; Wang W; Dong C; Ning Z; Liu X; Liu C; Du G; Sha C; Wang K; Lu J; Sun B; Zhao Y; Wang Q; Xu H; Li Y; Shen Z; Jiao J; Wang R; Tian J; Liu W; Wang L; Deng YQ; Dou C
Commun Biol; 2021 Apr; 4(1):500. PubMed ID: 33893388
[TBL] [Abstract][Full Text] [Related]
13. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
15. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
[TBL] [Abstract][Full Text] [Related]
16. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
[TBL] [Abstract][Full Text] [Related]
17. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
18.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
20. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.
Sheikhi A; Hojjat-Farsangi M
Hum Vaccin Immunother; 2021 Jan; 17(1):92-97. PubMed ID: 32663051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]